Giuseppe F. Amoruso

Crotone, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.

Upadacitinib is efficacious in reducing the alexithymic trait in adult patients with moderate-to-severe atopic dermatitis: a prospective multicenter real-life study.

Journal: Italian journal of dermatology and venereology

Published: October 03, 2025

JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).

JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).

Journal: Dermatology and therapy

Published: May 22, 2025

Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.

Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: December 05, 2024

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

Effective response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: A multicenter case series study.

Journal: Journal of the American Academy of Dermatology

Published: March 17, 2024

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis.

Journal: Journal of clinical medicine

Published: December 24, 2023

An Innovative Dual-Wavelength Laser Technique for Atrophic Acne Scar Management: A Pilot Study.

An Innovative Dual-Wavelength Laser Technique for Atrophic Acne Scar Management: A Pilot Study.

Journal: Medicina (Kaunas, Lithuania)

Published: October 12, 2023

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.

Journal: Paediatric drugs

Published: August 02, 2022

The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy.

The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy.

Journal: Clinics in dermatology

Published: November 17, 2021

Ixekizumab May Improve Renal Function in Psoriasis.

Ixekizumab May Improve Renal Function in Psoriasis.

Journal: Healthcare (Basel, Switzerland)

Published: April 06, 2021

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.

Journal: American journal of clinical dermatology

Published: March 16, 2021

A New 675 nm Laser Device in the Treatment of Facial Aging: A Prospective Observational Study.

A New 675 nm Laser Device in the Treatment of Facial Aging: A Prospective Observational Study.

Journal: Photobiomodulation, photomedicine, and laser surgery

Published: January 15, 2021

Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising.

Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising.

Journal: Dermatologic therapy

Published: September 14, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026